Bio Pharma Dive
NOVEMBER 23, 2020
Data from two late-stage trials showed the shot to be, on average, 70% effective against COVID-19, an encouraging finding. The lower dose tested, however, outperformed a higher dose.
World of DTC Marketing
NOVEMBER 24, 2020
SUMMARY : In a 2019 Pew Research Center poll, more Americans said they consider made-up news a bigger problem than terrorism, illegal immigration, racism, and sexism. And 68% said disinformation greatly impacts people’s confidence in government institutions. No matter the form, inaccurate health information is a danger to public health. While psychological factors leave people unguarded against misinformation, people in the U.S. are particularly vulnerable to health misinformation because the l
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
NY Times
NOVEMBER 27, 2020
Court filings reveal consultants’ talk of a records purge during the opioid crisis, and shed new light on sales advice given to the billionaire Sackler family and their drug company, Purdue Pharma.
BioSpace
NOVEMBER 23, 2020
As the Pfizer-BioNTech COVID-19 vaccine is being evaluated by the U.S. FDA and the Moderna vaccine is soon to follow, here’s a look at several of the top COVID-19 vaccine candidates and where they stand as of today.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Bio Pharma Dive
NOVEMBER 24, 2020
This year, the biotech spent about $27 billion trying to become a leader in cancer research. Executives who spoke to BioPharma Dive said there's still work to be done.
World of DTC Marketing
NOVEMBER 27, 2020
SUMMARY: Business by press release has made pharma executives a lot of money but we still haven’t seen any over reviewed data on COVID 19 vaccines. A report released Thursday by the University of California at Los Angeles researchers said that 66 percent of Los Angeles health-care workers who responded to an online questionnaire (not a randomized sample) said they would delay taking a vaccine.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
BioSpace
NOVEMBER 22, 2020
COVID-19 is a cardiac condition as much as it is a pulmonary or respiratory disease. This knowledge is so recent that it often is overlooked by non-cardiologists, according to physicians speaking at Demy-Colton Virtual Salon, “COVID-19: Surprising Cardiac Findings & Concern about the Potential Im.
Bio Pharma Dive
NOVEMBER 24, 2020
The drug, now known as Oxlumo, is the first approved treatment for patients with a potentially life-threatening condition that can cause kidney failure. Like other Alnylam drugs, it comes at a six-figure list price.
World of DTC Marketing
NOVEMBER 25, 2020
SUMMARY: This Thanksgiving, my thoughts turn to families who are going to have an empty seat at the table because of COVID-19. Over 2100 people died from COVID-19 yesterday as the void in leadership continues. Maybe I’m too empathetic, but these people are someone’s dad, father, son, or daughter, and many of these deaths could have been prevented if only we had leadership who put as much emphasis on prevention as they did on “fake news.” On Facebook, local newspaper feeds
NY Times
NOVEMBER 23, 2020
The billionaire is working with the W.H.O., drugmakers and nonprofits to defeat the coronavirus everywhere, including in the world’s poorest nations. Can they do it?
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
pharmaphorum
NOVEMBER 24, 2020
A merger involving two US digital health specialists and a blank cheque company has created a telemedicine player, called UpHealth, that is valued at more than $1.3 billion. The three-way deal combines UpHealth – which provides patient care management, telemedicine and digital pharmacy services and gives its name to the new group – with CloudBreak, which provides a video consultation platform for doctors and patients.
Bio Pharma Dive
NOVEMBER 23, 2020
The smaller biotech vowed to push forward, although the pill's inability to prevent heart failure death may complicate its plans to win approval.
World of DTC Marketing
NOVEMBER 23, 2020
SUMMARY: Pfizer’s ad in newspapers around the U.S. shows that they are ready to lead the fight against COVID-19 and in the process establish that their vaccine is safe and has been well tested. Pfizer ran an ad today that is superb. The ad, for it’s COVID-19 vaccine, has a headline that says “courage” and details that 43,661 people tested their vaccine and ends with “science will win” This ad send out a reassurance to vaccine skeptics who have come to believe
XTalks
NOVEMBER 26, 2020
MIT researchers developed an algorithm that has correctly identified asymptomatic people with COVID-19 by the sound of their forced coughs using their smartphone devices. The researchers have found that asymptomatic people may differ from healthy people in the way that they cough. These differences are not identifiable by the human ear, but the researchers have developed an AI that can detect this difference.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
pharmaphorum
NOVEMBER 27, 2020
A new EMA approval has expanded the use of Vertex Pharma’s exon-skipping cystic fibrosis therapy Symkevi to children as young as six if they have specific gene mutations. The regulator has given a green light to use of Symkevi (tezacaftor/ivacaftor) with Vertex’ Kalydeco (ivacaftor) in patients ages six years and older who have two copies of the F508del mutation in the CFTR gene, or one F508del copy and one of 14 other so-called “minimal function” mutations in CFTR.
Bio Pharma Dive
NOVEMBER 23, 2020
The large drugmaker will pay $425 million to acquire OncoImmune, which is developing a treatment for severe coronavirus disease.
BioSpace
NOVEMBER 22, 2020
Maryland-based vaccine company Novavax said its COVID-19 vaccine candidate, NVX?CoV2373, prevented SARS-CoV-2 infection in monkeys, hinting that the product could likewise prove effective in humans.
Scienmag
NOVEMBER 24, 2020
The restoration of grasslands in tropical semi-arid regions can both mitigate the impacts of climate change and restore key benefits healthy grasslands provide for pastoralists and agro-pastoralist communities Credit: CABI New research has demonstrated how, in contrast to encroachment by the invasive alien tree species Prosopis julifora (known as `Mathenge` -in Kenya or `Promi` in […].
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
pharmaphorum
NOVEMBER 27, 2020
Amanda Barrell explores how a perfect storm of changing economics, advances in technology, and the increasing volume of the patient voice is stoking change in the rare disease space. New models of drug development are fuelling life-changing advantages in the rare disease space, previously an economic no-go area for pharma and biotech companies. That was among the discussion points during Fighting Rare Diseases – The Science, Economics and the Patients , a webinar hosted by o2h Group.
Bio Pharma Dive
NOVEMBER 27, 2020
By teaming up with Sage, Biogen gets its hands on two drugs in mid- to late-stage testing for multiple types of depression and essential tremor.
BioSpace
NOVEMBER 23, 2020
Two months after he was stepped down from the role of chief executive officer of Legend Biotech, Fangliang “Frank” Zhang has been arrested for smuggling genetic resources from the People’s Republic of China.
BioPharma Reporter
NOVEMBER 23, 2020
Study data from leading COVID-19 vaccine candidates suggests they may be effective in older people.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
pharmaphorum
NOVEMBER 23, 2020
Janssen’s Daniel de Schryver tells us why it’s time to give patients a permanent seat at the table and improve health outcomes through patient-pharma dialogue. I’m struck by just how much we thrive when we share a common purpose; when – as a society, a group or a family unit – we work together to achieve the same goal. It’s no different in healthcare.
XTalks
NOVEMBER 24, 2020
For years, Beyond Meat and Impossible Foods have had a stronghold on the US plant-based meat market, a market that is expected to reach $27.9 billion by 2025. But with growing environmental and safety concerns over meat production and more people opting to eat less meat, new entrants are being welcomed with open arms in the growing market. Enter Modern Meat , a Vancouver, Canada-based meat alternative company that launched around two years ago and recently went public.
BioSpace
NOVEMBER 22, 2020
Eiger’s Zokinvy is the first-ever approved treatment for children with Huchinson-Gilford Progeria Syndrome and processing-deficient Progeroid Laminopathies.
Pharma Times
NOVEMBER 27, 2020
It is hoped that the test will help detect cancer at a much earlier stage
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
pharmaphorum
NOVEMBER 25, 2020
An artificial intelligence tool developed by GE Healthcare twinned with a mobile X-ray device can help the placement of endotracheal tubes (ETTs), a necessary step for COVID-19 patients who require ventilation. The new tool – part of GE’s Critical Care Suite 2.0 – helps bedside staff and radiologists assess patients before intubation and make sure ETTs are positioned correctly which should reduce complications.
NY Times
NOVEMBER 23, 2020
The drug maker said its vaccine candidate was 70 percent effective on average, and potentially up to 90 percent effective, at preventing Covid-19 in an early analysis.
BioSpace
NOVEMBER 23, 2020
Clene Nanomedicine is trying to set a new “gold standard” in neurodegenerative diseases through the development of a new class of drugs called bioenergetic nanotherapeutics that harnesses the properties of gold nanocrystals.
Pharma Times
NOVEMBER 27, 2020
Tepotinib could be the first treatment on the market for NSCLC in adults harbouring METex14 skipping alterations
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Expert insights. Personalized for you.
339 
Let's personalize your content